Related Experiment Videos
The calcium channel blocker controversy
1Department of Internal Medicine, The University of Texas Southwestern Medical Center at Dallas, 75235-8899, USA.
Insights
The safety concerns surrounding calcium channel blockers (CCBs) are largely unfounded for current hypertension treatments. Long-acting CCBs, unlike older short-acting versions, do not pose the same risks to patients, especially those with a history of myocardial infarction (MI).
Area of Science:
- Cardiology
- Pharmacology
- Hypertension Management
Background:
- A recent case-control study linked short-acting calcium channel blockers (CCBs) to increased risk of myocardial infarction (MI) in hypertensive patients.
- Older studies indicated elevated mortality rates with high-dose, short-acting nifedipine in post-MI patients.
Purpose of the Study:
- To address the controversy surrounding CCB safety in hypertension treatment.
- To differentiate the risks associated with short-acting CCBs from the safety profile of long-acting CCBs.
Main Methods:
- Review of a case-control study on CCB use and MI in hypertensive patients.
- Re-evaluation of historical studies on short-acting nifedipine and post-MI mortality.
- Analysis of current clinical practices regarding CCB formulations.
Main Results:
- The identified risks of short-acting CCBs are linked to specific formulations and dosages not reflective of current therapeutic standards.
- The danger of massive doses of short-acting nifedipine in post-MI patients is considered irrelevant to contemporary clinical practice.
- The safety concerns extrapolated from older studies do not apply to the current use of long-acting CCBs in managing hypertension.
Conclusions:
- The controversy regarding CCB safety is largely irrational and unfortunate.
- Current long-acting CCBs are safe and effective for hypertension management.
- Clinical decisions should differentiate between short-acting and long-acting CCB formulations.
Abstract:
A major controversy about the safety of calcium channel blockers (CCBs) has arisen since the publication of a case-control study showing that hypertensives who suffered an acute myocardial infarction (MI) were more likely than hypertensives who had not had an MI to be taking one of these (short-acting) agents than other antihypertensive agents. This study was accompanied by a republication of older studies showing that large doses of short-acting nifedipine given to post-MI patients increased their mortality rate. The danger of massive doses of short-acting nifedipine in a post-MI patient is real but irrelevant to current practice. On the other hand, the putative dangers of short-acting CCBs in the treatment of hypertension do not apply to the current use of long-acting CCBs. Therefore the scare over their use is both irrational and unfortunate.